US FDA panel backs Paladin Labs' parasitic disease drug

US FDA panel backs Paladin Labs' parasitic disease drug

If Impavido is approved, Paladin, which is based in Montreal, Canada, would receive a voucher from the FDA giving it the right to receive a priority review of future product that might not otherwise qualify for such a review. Such vouchers, designed to 

4
Like
Save

Comments

Write a comment

*